Olema Pharmaceuticals (OLMA) Change in Accured Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Change in Accured Expenses for 7 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 111.59% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $23.5 million (up 6474.3% YoY), while the FY2025 annual figure was $11.0 million, down 1.95% from the prior year.
• Change in Accured Expenses retreated to $1.3 million in Q1 2026 per OLMA's latest filing, from $3.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $12.7 million in Q2 2025 and bottomed at -$11.2 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of $2.2 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 2481.42% — and 2025, when it sank 2684.16%.
• Olema Pharmaceuticals' Change in Accured Expenses stood at $3.7 million in 2022, then soared by 38.37% to $5.2 million in 2023, then slumped by 56.87% to $2.2 million in 2024, then surged by 62.83% to $3.6 million in 2025, then slumped by 64.09% to $1.3 million in 2026.
• Business Quant data shows OLMA's Change in Accured Expenses at $1.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.9 million in Q3 2025.